FDA inspection
GlaxoSmithKline Consumer Healthcare: FDA inspection ending Jan 9, 2003
FDA inspection 252790 · Voluntary Action Indicated (VAI) · Jersey City, NJ
Key facts
| Inspection ID | 252790 |
|---|---|
| Firm | GlaxoSmithKline Consumer Healthcare |
| FEI number | 2210284 |
| Address | 257 Cornelison Ave |
| City | Jersey City |
| State | NJ |
| ZIP | 07302-3113 |
| Fiscal year | 2003 |
| Inspection end date | Jan 9, 2003 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data